SEC Form 4 · accession 0001682852-26-000167
Moderna, Inc. · MRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shannon Thyme Klinger
Officer — Chief Legal Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 3, 2026 · 4:56 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001682852
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2026 | M | 3,471 | $30.96 | A | 77,600 | D | |
| Common Stock | Sep 1, 2026 | S | 3,471 | $139.95 | D | 74,129 | D | |
| Common StockF2 | Sep 1, 2026 | M | 2,166 | — | A | 76,295 | D | |
| Common Stock | Sep 1, 2026 | F | 1,048 | $140.34 | D | 75,247 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $30.96 | Sep 1, 2026 | M | 3,471 | D | Mar 1, 2026 | Mar 1, 2035 | Common Stock | 3,471 | 34,716 | D |
| Restricted Stock UnitsF2,F5 | — | Sep 1, 2026 | M | 2,166 | D | — | — | Common Stock | 2,166 | 21,661 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025.
- F2Restricted stock units convert into common stock on a one-for-one basis.
- F3Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
- F425% of this option vested and became exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
- F525% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.